Table 4. Clinical deterioration in patients with or without neoadjuvant chemotherapy during the three-year follow-up period.
| Variables | Deterioration, N (%)* | Adjusted OR (95% CI)† | Adjusted P† |
|---|---|---|---|
| Neoadjuvant | 0.01 | ||
| Yes (N=114) | 15 (13.2) | 2.9 (1.3, 6.5) | |
| No (N=249) | 20 (8.0) | 1 | |
| Tumor differentiation | 0.63 | ||
| Poorly differentiated | 5 (13.9) | 2.0 (0.7, 5.7) | |
| Well differentiated | 0 (0.0) | - | |
| Undifferentiated | 2 (8.3) | 0.7 (0.1, 3.5) | |
| Moderately differentiated | 28 (9.4) | 1 | |
| Clinical stage | 0.17 | ||
| IB2 | 12 (13.6) | 2.5 (0.8, 8.1) | |
| IIA1 | 18 (8.2) | 1.2 (0.4, 3.8) | |
| IIA2 | 5 (9.1) | 1 | |
| Vascular tumor thrombus | < 0.01 | ||
| Yes | 26 (14.5) | 4.2 (1.8, 9.7) | |
| No | 9 (4.9) | 1 | |
| Postoperative radiation therapy | 0.59 | ||
| Yes | 27 (9.7) | 0.8 (0.3, 1.9) | |
| No | 8 (9.5) | 1 |
*, one patient died due to non-cancerous cause during the second year and was not counted into the analysis. †, OR and P for neoadjuvant chemotherapy were adjusted for tumor differentiation, clinical stage, vascular tumor thrombus, and postoperative radiation therapy.